Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Minimal Residual Disease 'Coming Soon' As An Approval Endpoint, Celgene Says

Dec 13 2017

• By Sue Sutter

Coming soon

Related Content

Supplemental Oncology Approvals: 'Reverse Accelerated Approval,' Not Lowering The Bar

Nov 27 2017

Celgene's CAR-T Leadership Goals Advance At ASH 2017

Dec 12 2017

Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate

Sep 21 2016

Related Companies

Bristol Myers Squibb Company

Genetix Biotherapeutics

Johnson & Johnson

Additional Topics

United States Drug Approval Standards Review Pathway Regulation Cancer BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window